Search

Your search keyword '"Ballester, Leomar Y."' showing total 473 results
Start Over Author "Ballester, Leomar Y."
473 results on '"Ballester, Leomar Y."'

1. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

Author

Amara, Chandra Sekhar, Kami Reddy, Karthik Reddy, Yuntao, Yang, Chan, Yuen San, Piyarathna, Danthasinghe Waduge Badrajee, Dobrolecki, Lacey Elizabeth, Shih, David J. H., Shi, Zhongcheng, Xu, Jun, Huang, Shixia, Ellis, Matthew J., Apolo, Andrea B., Ballester, Leomar Y., Gao, Jianjun, Hansel, Donna E., Lotan, Yair, Hodges, H. Courtney, Lerner, Seth P., Creighton, Chad J., Sreekumar, Arun, Zheng, W. Jim, Msaouel, Pavlos, Kavuri, Shyam M., and Putluri, Nagireddy

Published
2024
Full Text
View/download PDF

3. Utility of Whole Slide Imaging for Intraoperative Consultation: Experience of a Large Academic Center

Author

Shehabeldin, Ahmed, Rohra, Prih, Sellen, Linton D., Zhao, Jianping, Alqaidy, Doaa, Aramin, Hermineh, Hameed, Nadia, Perez, Ydamis Estrella, Lai, Zongshan, Tong, Yi Tat, Milton, Denai R., Edgerton, Mary E., Fuller, Gregory, Hansel, Donna, Prieto, Victor G., Ballester, Leomar Y., and Aung, Phyu P.

Subjects
Technology application, Evaluation, Innovations, Imaging technology, Imaging systems -- Evaluation, Pathology -- Innovations -- Technology application
Abstract

Whole slide imaging involves high-resolution scanning of glass slides (GSs) prepared from formalin-fixed, paraffin-embedded tissue to create digital images that can be reviewed through digital platforms. The main components of [...], * Context.--In the United States, review of digital whole slide images (WSIs) using specific systems is approved for primary diagnosis but has not been implemented for intraoperative consultation. Objective.--To evaluate the safety of review of WSIs and compare the efficiency of review of WSIs and glass slides (GSs) for intraoperative consultation. Design.--Ninety-one cases previously submitted for frozen section evaluation were randomly selected from 8 different anatomic pathology subspecialties. GSs from these cases were scanned on a Leica Aperio AT2 scanner at x 20 magnification (0.25 [micro]m/pixel). The slides were deidentified, and a short relevant clinical history was provided for each slide. Nine board-certified general pathologists who do not routinely establish primary diagnoses using WSIs reviewed the WSIs using Leica Aperio ImageScope viewing software. After a washout period of 2-3 weeks, the pathologists reviewed the corresponding GSs using a light microscope (Olympus BX43). The pathologists recorded the diagnosis and time to reach the diagnosis. Intraobserver concordance, time to diagnosis, and specificity and sensitivity compared to the original diagnosis were evaluated. Results.--The rate of intraobserver concordance between GS results and WSI results was 93.7%. Mean time to diagnosis was 1.25 minutes for GSs and 1.76 minutes for WSIs (P < .001). Specificity was 91% for GSs and 90% for WSIs; sensitivity was 92% for GSs and 92% for WSIs. Conclusions.--Time to diagnosis was longer with WSIs than with GSs, and scanning GSs and uploading the data to whole slide imaging systems takes time. However, review of WSIs appears to be a safe alternative to review of GSs. Use of WSIs allows reporting from a remote site during a public health emergency such as the COVID-19 pandemic and facilitates subspecialty histopathology services. (Arch Pathol Lab Med. 2024;148:715-721; doi: 10.5858/arpa.2023-0105-OA)

Published
2024
Full Text
View/download PDF

6. Rapid detection of mutations in CSF‑cfTNA with the Genexus Integrated Sequencer

Author

Sheehan, Jason, moderator, D'Amico, Randy, moderator, Esquenazi, Yoshua, speaker, and Ballester, Leomar Y, speaker

Abstract

Join the Journal of Neuro-Oncology's Editor-in-Chief, Dr. Jason Sheehan, and Associate Editor, Dr. Randy D'Amico, for a conversation with Dr. Yoshua Esquenazi Levy and Dr. Leomar Y. Ballester from the University of Texas MD Anderson Cancer Center to discuss their latest publication on the rapid detection of mutations in CSF‑cfTNA with the Genexus Integrated Sequencer.

Published
2024
Full Text
View/download PDF

7. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab

Author

Lu, Guangrong, Zhu, Ping, Rao, Mayank, Linendoll, Nadine, Buja, L. Maximilian, Bhattacharjee, Meenakshi B., Brown, Robert E., Ballester, Leomar Y., Tian, Xuejun, Pilichowska, Monika, Wu, Julian K., Hergenroeder, Georgene W., Glass, Williams F., Chen, Lei, Zhang, Rongzhen, Pillai, Anil K., Hunter, Robert L., and Zhu, Jay-Jiguang

Published
2022
Full Text
View/download PDF

9. Tumors of the Central Nervous System

Author

Velázquez Vega, José E., Ballester, Leomar Y., Schniederjan, Matthew J., Lin, Fan, Series Editor, Yang, Ximing J., Series Editor, Ding, Yi, editor, and Zhang, Linsheng, editor

Published
2021
Full Text
View/download PDF

18. MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas.

Author

Ozkizilkaya, Hanim I., Vinocha, Anjali, Dono, Antonio, Ogunbona, Oluwaseun Basit, Toruner, Gokce A., Aung, Phyu P., Kamiya Matsuoka, Carlos, Esquenazi, Yoshua, DeMonte, Franco, and Ballester, Leomar Y.

Subjects
RESEARCH funding, TUMOR markers, RETROSPECTIVE studies, DESCRIPTIVE statistics, IMMUNOHISTOCHEMISTRY, MONOCLONAL antibodies, MENINGIOMA, MEDICAL records, ACQUISITION of data, GENE expression profiling, FLUORESCENCE in situ hybridization, TRANSFERASES, STAINS & staining (Microscopy), CYCLIN-dependent kinases, SEQUENCE analysis, CHEMICAL inhibitors
Abstract

Simple Summary: Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss is a key factor in diagnosing meningiomas as Central Nervous System (CNS) WHO grade 3 tumors. Typically, detecting this gene loss involves costly and complex techniques like sequencing or FISH. However, the MTAP gene, which is located near CDKN2A/B on the same chromosome, may provide a more accessible way to detect these losses through a simpler, more affordable test called immunohistochemistry (IHC). This study explored different concentrations and antibodies for MTAP and p16 across two institutions to evaluate their potential as surrogate markers for CDKN2A/B loss. The results showed that p16 expression varied and did not align with either MTAP expression or CDKN2A FISH results. This study suggests that IHC for MTAP is a promising, cost-effective method for identifying high-grade meningiomas, offering a quicker and less expensive alternative to existing techniques. Background: Homozygous cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss is one of the parameters that support the designation of meningiomas as Central Nervous System (CNS) WHO grade 3 tumors. Evaluation of CDKN2A/B by sequencing or Fluorescence in situ hybridization (FISH) is costly and not always readily accessible. An immunohistochemistry (IHC)-based marker for the evaluation of CDKN2A/B loss would provide faster results at a lower cost. Methods: This retrospective study included patients diagnosed with meningioma at our institution between 2016 and 2019. Archival tumor tissue was used for analysis. MTAP immunohistochemistry (IHC) was performed at various dilutions (1:1200, 1:400, 1:200, 1:100) using two different antibodies, and p16 IHC was conducted simultaneously. These analyses were carried out at two different institutions. To determine the sensitivity and specificity of MTAP and p16 as surrogate markers for CDKN2A/B loss, CDKN2A FISH was utilized as the gold standard. Results: Overall, 46/49 tumors showed strong MTAP staining (94%) at institution 1, and 44/49 (90%) showed either faint positive or positive results at institution 2. One grade 3 meningioma that demonstrated homozygous CDKN2A loss by FISH also showed loss of MTAP expression by IHC. One grade 2 meningioma showed regional CDKN2A loss by FISH and variable MTAP expression under different IHC conditions. MTAP expression evaluation was superior at a dilution of 1:100 with the Abnova Anti-MTAP Monoclonal antibody. Conclusions: P16 expression was variable and did not correlate with either MTAP expression or CDKN2A FISH results. MTAP IHC is a promising surrogate marker for the evaluation of CDKN2A status in meningiomas. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors

Author

Zheng, Lan, primary, Luthra, Rajyalakshmi, additional, Alvarez, Hector A., additional, San Lucas, F. Anthony, additional, Duose, Dzifa Y., additional, Wistuba, Ignacio I., additional, Fuller, Gregory N., additional, Ballester, Leomar Y., additional, Roy-Chowdhuri, Sinchita, additional, Sweeney, Keith J., additional, Rashid, Asif, additional, Yang, Richard K., additional, Chen, Wei, additional, Liu, Audrey, additional, Wu, Yun, additional, Albarracin, Constance, additional, Patel, Keyur P., additional, Routbort, Mark J., additional, Sahin, Aysegul A., additional, Ding, Qingqing, additional, and Chen, Hui, additional

Published
2023
Full Text
View/download PDF

36. Utility of Whole Slide Imaging for Intraoperative Consultation: Experience of a Large Academic Center

Author

Shehabeldin, Ahmed, primary, Rohra, Prih, additional, Sellen, Linton D., additional, Zhao, Jianping, additional, Alqaidy, Doaa, additional, Aramin, Hermineh, additional, Hameed, Nadia, additional, Perez, Ydamis Estrella, additional, Lai, Zongshan, additional, Tong, Yi Tat, additional, Milton, Denái R., additional, Edgerton, Mary E., additional, Fuller, Gregory, additional, Hansel, Donna, additional, Prieto, Victor G., additional, Ballester, Leomar Y., additional, and Aung, Phyu P., additional

Published
2023
Full Text
View/download PDF

41. Glioma and temozolomide induced alterations in gut microbiome

Author

Patrizz, Anthony, Dono, Antonio, Zorofchian, Soheil, Hines, Gabriella, Takayasu, Takeshi, Husein, Nuruddin, Otani, Yoshihiro, Arevalo, Octavio, Choi, H. Alex, Savarraj, Jude, Tandon, Nitin, Ganesh, Bhanu P., Kaur, Balveen, McCullough, Louise D., Ballester, Leomar Y., and Esquenazi, Yoshua

Published
2020
Full Text
View/download PDF

46. SDPS-44 RAPID DETECTION OF MUTATIONS IN CSF-CFTNA WITH THE GENEXUS INTEGRATED SEQUENCER

Author

Arjuna, Srividya, primary, Shah, Mauli, additional, Dono, Antonio, additional, Pichardo, Pavel, additional, Nunez-Rubiano, Luis, additional, Zhu, Jay-Jiguang, additional, Riascos-Castaneda, Roy F, additional, Luthra, Rajyalakshmi, additional, Roy-Chowdhuri, Sinchita, additional, Duose, Dzifa, additional, Lang, Frederick F, additional, Esquenazi, Yoshua, additional, and Ballester, Leomar Y, additional

Published
2023
Full Text
View/download PDF

48. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Author

Rajan, Arun, Heery, Christopher R., Thomas, Anish, Mammen, Andrew L., Perry, Susan, O’Sullivan Coyne, Geraldine, Guha, Udayan, Berman, Arlene, Szabo, Eva, Madan, Ravi A., Ballester, Leomar Y., Pittaluga, Stefania, Donahue, Renee N., Tsai, Yo-Ting, Lepone, Lauren M., Chin, Kevin, Ginty, Fiona, Sood, Anup, Hewitt, Stephen M., Schlom, Jeffrey, Hassan, Raffit, and Gulley, James L.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results